Holy cow listen from 48min-52 the UC P2 trial is so successful that it could be stopped and go into P3 quickly and could be very small and short due to the stark contrast between experiemental and control patients. 100% of rex group responded and went into remission and 0% of controls improved. very unusual and spectacular!MOA clear and biomarkers now clear and endoscopic end point is clear and short and acceptable to FDA for approval.
Ann: MSB Q2 Financial Results and Operational Highlights, page-50
-
- There are more pages in this discussion • 170 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.010(0.69%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.49 | $1.44 | $3.472M | 2.379M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12398 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 5440 | 3 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |